Controlled Phase 2 Study of Ipilimumab Shows Clinical Activity in Advanced Non-Small Cell Lung Cancer.
Linked as:
Extract
Controlled Phase 2 Study of Ipilimumab Shows Clinical Activity in Advanced Non-Small Cell Lung Cancer.
Study of Investigational Immuno-Oncology Agent Meets Primary Endpoint of Efficacy; Planning for Phase 3 Study Underway
Results to be Presented at 46(th) Annual Meeting of the American Society of Clinical Oncology PRINCETON, N.J. -- Bristol-Myers Squibb Company (NYSE: BMY) today announced positive results from a randomized Pha...See the full content of this document
Sponsored links
